Cargando…
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SA...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538139/ https://www.ncbi.nlm.nih.gov/pubmed/34696252 http://dx.doi.org/10.3390/vaccines9101143 |
_version_ | 1784588433691246592 |
---|---|
author | Bianchi, Francesco Paolo Tafuri, Silvio Migliore, Giovanni Vimercati, Luigi Martinelli, Andrea Lobifaro, Annamaria Diella, Giusy Stefanizzi, Pasquale |
author_facet | Bianchi, Francesco Paolo Tafuri, Silvio Migliore, Giovanni Vimercati, Luigi Martinelli, Andrea Lobifaro, Annamaria Diella, Giusy Stefanizzi, Pasquale |
author_sort | Bianchi, Francesco Paolo |
collection | PubMed |
description | To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January–May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4–99.0%) at 14–34 days after the first dose, and 94.8% (87.0–97.8%), 83.0% (65.0–92.0%), and 81.0% (42.0–94.0%) at 14–41, 42–69, and >69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4–99.8%) at 14–34 days after the first dose and 97.2% (90.3–99.2%), 85.0% (63.0–94.2%), and 88.0% (42.0–97.6%) at 14–41, 42–69, and >69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population. |
format | Online Article Text |
id | pubmed-8538139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85381392021-10-24 BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study Bianchi, Francesco Paolo Tafuri, Silvio Migliore, Giovanni Vimercati, Luigi Martinelli, Andrea Lobifaro, Annamaria Diella, Giusy Stefanizzi, Pasquale Vaccines (Basel) Article To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January–May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4–99.0%) at 14–34 days after the first dose, and 94.8% (87.0–97.8%), 83.0% (65.0–92.0%), and 81.0% (42.0–94.0%) at 14–41, 42–69, and >69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4–99.8%) at 14–34 days after the first dose and 97.2% (90.3–99.2%), 85.0% (63.0–94.2%), and 88.0% (42.0–97.6%) at 14–41, 42–69, and >69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population. MDPI 2021-10-07 /pmc/articles/PMC8538139/ /pubmed/34696252 http://dx.doi.org/10.3390/vaccines9101143 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bianchi, Francesco Paolo Tafuri, Silvio Migliore, Giovanni Vimercati, Luigi Martinelli, Andrea Lobifaro, Annamaria Diella, Giusy Stefanizzi, Pasquale BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title | BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title_full | BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title_fullStr | BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title_full_unstemmed | BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title_short | BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study |
title_sort | bnt162b2 mrna covid-19 vaccine effectiveness in the prevention of sars-cov-2 infection and symptomatic disease in five-month follow-up: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538139/ https://www.ncbi.nlm.nih.gov/pubmed/34696252 http://dx.doi.org/10.3390/vaccines9101143 |
work_keys_str_mv | AT bianchifrancescopaolo bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT tafurisilvio bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT miglioregiovanni bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT vimercatiluigi bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT martinelliandrea bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT lobifaroannamaria bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT diellagiusy bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT stefanizzipasquale bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy AT bnt162b2mrnacovid19vaccineeffectivenessinthepreventionofsarscov2infectionandsymptomaticdiseaseinfivemonthfollowuparetrospectivecohortstudy |